Novo Nordisk Wegovy Pill Reaches Over 18000 US Prescriptions in First Full Week
Novo Nordisk recorded 18,410 prescriptions for its Wegovy pill in the first full week. This strong start helps the company compete with rival Eli Lilly.
洞察:
Novo Nordisk A/S recorded 18,410 prescriptions in the US 
USfor its new Wegovy pill during the medication's first full week of availability. The oral weight-loss treatment, which officially launched on January 5, 2026, had previously hit 3,071 prescriptions within the first four days after its release. Data from IQVIA, shared by an analyst on Friday, January 23, 2026, indicates that the pill is currently tracking ahead of other historical GLP-1 product launches.
USfor its new Wegovy pill during the medication's first full week of availability. The oral weight-loss treatment, which officially launched on January 5, 2026, had previously hit 3,071 prescriptions within the first four days after its release. Data from IQVIA, shared by an analyst on Friday, January 23, 2026, indicates that the pill is currently tracking ahead of other historical GLP-1 product launches.Guggenheim analysts noted the significance of these early adoption metrics as the pharmaceutical industry prepares for a competitive shift in the GLP-1 weight-loss medication market. While Wegovy previously existed only in an injectable form, the new oral formulation provides patients with a needle-free alternative and greater flexibility in their treatment. Despite the introduction of oral options, injectable medications are still expected to dominate the weight-loss market for years to come.
